Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Ab Initio Raman Spectra of β-Lactamase Inhibitor Intermediates Bound to E166A SHV β-Lactamase.

Miani A, Helfand MS, Raugei S.

J Chem Theory Comput. 2009 Aug 11;5(8):2158-72. doi: 10.1021/ct900131q.

PMID:
26613155
2.

Inhibition of OXA-1 beta-lactamase by penems.

Bethel CR, Distler AM, Ruszczycky MW, Carey MP, Carey PR, Hujer AM, Taracila M, Helfand MS, Thomson JM, Kalp M, Anderson VE, Leonard DA, Hujer KM, Abe T, Venkatesan AM, Mansour TS, Bonomo RA.

Antimicrob Agents Chemother. 2008 Sep;52(9):3135-43. doi: 10.1128/AAC.01677-07. Epub 2008 Jun 16.

3.

Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamase.

Totir MA, Helfand MS, Carey MP, Sheri A, Buynak JD, Bonomo RA, Carey PR.

Biochemistry. 2007 Aug 7;46(31):8980-7. Epub 2007 Jul 13.

4.

Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitors.

Helfand MS, Taracila MA, Totir MA, Bonomo RA, Buynak JD, van den Akker F, Carey PR.

Biochemistry. 2007 Jul 24;46(29):8689-99. Epub 2007 Jun 27.

PMID:
17595114
5.

Structure and Raman spectrum of clavulanic acid in aqueous solution.

Miani A, Raugei S, Carloni P, Helfand MS.

J Phys Chem B. 2007 Mar 15;111(10):2621-30. Epub 2007 Feb 16.

PMID:
17302447
6.

Extended-spectrum beta-lactamases in multidrug-resistant Escherichia coli: changing the therapy for hospital-acquired and community-acquired infections.

Helfand MS, Bonomo RA.

Clin Infect Dis. 2006 Dec 1;43(11):1415-6. Epub 2006 Oct 25. No abstract available.

PMID:
17083013
7.

Rational design of a beta-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 A crystal structure of wt SHV-1 complex with a penam sulfone.

Padayatti PS, Sheri A, Totir MA, Helfand MS, Carey MP, Anderson VE, Carey PR, Bethel CR, Bonomo RA, Buynak JD, van den Akker F.

J Am Chem Soc. 2006 Oct 11;128(40):13235-42.

8.

Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediates.

Totir MA, Padayatti PS, Helfand MS, Carey MP, Bonomo RA, Carey PR, van den Akker F.

Biochemistry. 2006 Oct 3;45(39):11895-904.

9.

Role of Asp104 in the SHV beta-lactamase.

Bethel CR, Hujer AM, Hujer KM, Thomson JM, Ruszczycky MW, Anderson VE, Pusztai-Carey M, Taracila M, Helfand MS, Bonomo RA.

Antimicrob Agents Chemother. 2006 Dec;50(12):4124-31. Epub 2006 Sep 18.

10.

Orally administered recombinant metallo-beta-lactamase preserves colonization resistance of piperacillin-tazobactam-treated mice.

Stiefel U, Harmoinen J, Koski P, Kääriäinen S, Wickstrand N, Lindevall K, Pultz NJ, Bonomo RA, Helfand MS, Donskey CJ.

Antimicrob Agents Chemother. 2005 Dec;49(12):5190-1. No abstract available.

12.

High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 {beta}-lactamase.

Padayatti PS, Helfand MS, Totir MA, Carey MP, Carey PR, Bonomo RA, van den Akker F.

J Biol Chem. 2005 Oct 14;280(41):34900-7. Epub 2005 Jul 29.

13.

Clavulanic acid inactivation of SHV-1 and the inhibitor-resistant S130G SHV-1 beta-lactamase. Insights into the mechanism of inhibition.

Sulton D, Pagan-Rodriguez D, Zhou X, Liu Y, Hujer AM, Bethel CR, Helfand MS, Thomson JM, Anderson VE, Buynak JD, Ng LM, Bonomo RA.

J Biol Chem. 2005 Oct 21;280(42):35528-36. Epub 2005 Jun 29.

14.

Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 beta-lactamase: defining a unique family of class C enzymes.

Hujer KM, Hamza NS, Hujer AM, Perez F, Helfand MS, Bethel CR, Thomson JM, Anderson VE, Barlow M, Rice LB, Tenover FC, Bonomo RA.

Antimicrob Agents Chemother. 2005 Jul;49(7):2941-8.

15.

Mechanisms by which anaerobic microbiota inhibit the establishment in mice of intestinal colonization by vancomycin-resistant Enterococcus.

Pultz NJ, Stiefel U, Subramanyan S, Helfand MS, Donskey CJ.

J Infect Dis. 2005 Mar 15;191(6):949-56. Epub 2005 Feb 11.

PMID:
15717271
16.

Effect of parenteral antibiotic administration on establishment of intestinal colonization by Candida glabrata in adult mice.

Pultz NJ, Stiefel U, Ghannoum M, Helfand MS, Donskey CJ.

Antimicrob Agents Chemother. 2005 Jan;49(1):438-40.

17.

In vitro antienterococcal activity explains associations between exposures to antimicrobial agents and risk of colonization by multiresistant enterococci.

Rice LB, Lakticová V, Helfand MS, Hutton-Thomas R.

J Infect Dis. 2004 Dec 15;190(12):2162-6. Epub 2004 Nov 16.

PMID:
15551215
18.
19.

Efficacy of oral ramoplanin for inhibition of intestinal colonization by vancomycin-resistant enterococci in mice.

Stiefel U, Pultz NJ, Helfand MS, Donskey CJ.

Antimicrob Agents Chemother. 2004 Jun;48(6):2144-8.

21.

Beta-lactam antibiotics and gastrointestinal colonization with vancomycin-resistant enterococci.

Rice LB, Hutton-Thomas R, Lakticova V, Helfand MS, Donskey CJ.

J Infect Dis. 2004 Mar 15;189(6):1113-8. Epub 2004 Mar 1.

PMID:
14999616
22.

Tazobactam inactivation of SHV-1 and the inhibitor-resistant Ser130 -->Gly SHV-1 beta-lactamase: insights into the mechanism of inhibition.

Pagan-Rodriguez D, Zhou X, Simmons R, Bethel CR, Hujer AM, Helfand MS, Jin Z, Guo B, Anderson VE, Ng LM, Bonomo RA.

J Biol Chem. 2004 May 7;279(19):19494-501. Epub 2004 Feb 2.

23.

Tazobactam forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV-1 beta-lactamase: 1.63 A crystal structure.

Padayatti PS, Helfand MS, Totir MA, Carey MP, Hujer AM, Carey PR, Bonomo RA, van den Akker F.

Biochemistry. 2004 Feb 3;43(4):843-8.

PMID:
14744126
24.
25.

Oral administration of beta-lactamase preserves colonization resistance of piperacillin-treated mice.

Stiefel U, Pultz NJ, Harmoinen J, Koski P, Lindevall K, Helfand MS, Donskey CJ.

J Infect Dis. 2003 Nov 15;188(10):1605-9. Epub 2003 Oct 23.

PMID:
14624388
26.

Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallography.

Helfand MS, Totir MA, Carey MP, Hujer AM, Bonomo RA, Carey PR.

Biochemistry. 2003 Nov 25;42(46):13386-92. Erratum in: Biochemistry. 2003 Dec 30;42(51):15398.

PMID:
14621983
27.

Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130.

Helfand MS, Bethel CR, Hujer AM, Hujer KM, Anderson VE, Bonomo RA.

J Biol Chem. 2003 Dec 26;278(52):52724-9. Epub 2003 Oct 8.

28.

Role of fecal incontinence in contamination of the environment with vancomycin-resistant enterococci.

Mayer RA, Geha RC, Helfand MS, Hoyen CK, Salata RA, Donskey CJ.

Am J Infect Control. 2003 Jun;31(4):221-5.

PMID:
12806359
29.

Beta-lactamases: a survey of protein diversity.

Helfand MS, Bonomo RA.

Curr Drug Targets Infect Disord. 2003 Mar;3(1):9-23. Review.

PMID:
12570729
30.
31.

Unexpected advanced generation cephalosporinase activity of the M69F variant of SHV beta-lactamase.

Helfand MS, Hujer AM, Sönnichsen FD, Bonomo RA.

J Biol Chem. 2002 Dec 6;277(49):47719-23. Epub 2002 Sep 26.

32.

Recurrence of vancomycin-resistant Enterococcus stool colonization during antibiotic therapy.

Donskey CJ, Hoyen CK, Das SM, Helfand MS, Hecker MT.

Infect Control Hosp Epidemiol. 2002 Aug;23(8):436-40.

PMID:
12186208
33.
34.

Immune activation, allergic drug toxicity and mortality in HIV-positive tuberculosis.

Wallis RS, Helfand MS, Whalen CC, Johnson JL, Mugerwa RD, Vjecha M, Okwera A, Ellner JJ.

Tuber Lung Dis. 1996 Dec;77(6):516-23.

PMID:
9039444
35.

T. H. Huxley's "Evolution and Ethics": the politics of evolution and the evolution of politics.

Helfand MS.

Vic Stud. 1977;20(2):159-77. No abstract available.

PMID:
11618259

Supplemental Content

Loading ...
Support Center